Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Interest Expenses (2020 - 2022)

Historic Interest Expenses for Inhibikase Therapeutics (IKT) over the last 3 years, with Q1 2022 value amounting to $5.0.

  • Inhibikase Therapeutics' Interest Expenses fell 9995.76% to $5.0 in Q1 2022 from the same period last year, while for Dec 2022 it was $5.0, marking a year-over-year decrease of 9997.49%. This contributed to the annual value of $19923.0 for FY2021, which is 3223.93% down from last year.
  • Per Inhibikase Therapeutics' latest filing, its Interest Expenses stood at $5.0 for Q1 2022, which was down 9995.76% from $158.0 recorded in Q4 2021.
  • Over the past 5 years, Inhibikase Therapeutics' Interest Expenses peaked at $11797.0 during Q1 2021, and registered a low of $5.0 during Q1 2022.
  • Moreover, its 3-year median value for Interest Expenses was $7139.0 (2020), whereas its average is $5481.1.
  • As far as peak fluctuations go, Inhibikase Therapeutics' Interest Expenses skyrocketed by 5888.22% in 2021, and later plummeted by 9995.76% in 2022.
  • Over the past 3 years, Inhibikase Therapeutics' Interest Expenses (Quarter) stood at $7139.0 in 2020, then plummeted by 97.79% to $158.0 in 2021, then tumbled by 96.84% to $5.0 in 2022.
  • Its Interest Expenses was $5.0 in Q1 2022, compared to $158.0 in Q4 2021 and $157.0 in Q3 2021.